...
search icon
tcrt-img

Alaunos Therapeutics Inc, Common Stock

TCRT

NAQ

$1.62

+$0

(0%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$2.59M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
5.66K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
-0.50
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$1.5 L
$26 H
$1.62

About Alaunos Therapeutics Inc, Common Stock

Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology. The company was founded in 2003 and is headquartered in Houston, Texas. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameTCRTSectorS&P500
1-Week Return-0.31%-0.03%1.53%
1-Month Return-10.5%4.56%4.75%
3-Month Return-30.7%1.29%2.77%
6-Month Return-33.06%-3.54%12.18%
1-Year Return-91.47%1.59%22.34%
3-Year Return-98.69%13.55%38.91%
5-Year Return-99.66%40.85%80.7%
10-Year Return-99.89%105.52%190.95%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue--398.00K2.92M5.00K[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":13.62,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":0.17,"profit":true}]
Cost of Revenue629.00K1.13M740.00K2.76M4.80M[{"date":"2019-12-31","value":13.1,"profit":true},{"date":"2020-12-31","value":23.49,"profit":true},{"date":"2021-12-31","value":15.41,"profit":true},{"date":"2022-12-31","value":57.44,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Profit(629.00K)(1.13M)(342.00K)163.00K(4.80M)[{"date":"2019-12-31","value":-385.89,"profit":false},{"date":"2020-12-31","value":-692.02,"profit":false},{"date":"2021-12-31","value":-209.82,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-2943.56,"profit":false}]
Gross Margin(Infinity%)(Infinity%)(85.93%)5.58%(95960.00%)[{"date":"2019-12-31","value":null,"profit":false},{"date":"2020-12-31","value":null,"profit":false},{"date":"2021-12-31","value":-1540.41,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-1720215.46,"profit":false}]
Operating Expenses57.86M80.36M77.21M38.16M29.47M[{"date":"2019-12-31","value":72,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":96.08,"profit":true},{"date":"2022-12-31","value":47.49,"profit":true},{"date":"2023-12-31","value":36.67,"profit":true}]
Operating Income2.26M(80.36M)(77.55M)(35.10M)(34.27M)[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-3549.51,"profit":false},{"date":"2021-12-31","value":-3425.31,"profit":false},{"date":"2022-12-31","value":-1550.57,"profit":false},{"date":"2023-12-31","value":-1513.56,"profit":false}]
Total Non-Operating Income/Expense-385.00K(2.38M)(5.78M)(3.68M)[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-619.22,"profit":false},{"date":"2022-12-31","value":-1501.04,"profit":false},{"date":"2023-12-31","value":-956.36,"profit":false}]
Pre-Tax Income(117.80M)(79.98M)(78.75M)(37.73M)(35.14M)[{"date":"2019-12-31","value":-11779600000,"profit":false},{"date":"2020-12-31","value":-7997600000,"profit":false},{"date":"2021-12-31","value":-7875100000,"profit":false},{"date":"2022-12-31","value":-3773000000,"profit":false},{"date":"2023-12-31","value":-3514000000,"profit":false}]
Income Taxes60.12M(1.13M)(1.86M)(133.00K)2.15M[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-1.88,"profit":false},{"date":"2021-12-31","value":-3.09,"profit":false},{"date":"2022-12-31","value":-0.22,"profit":false},{"date":"2023-12-31","value":3.57,"profit":true}]
Income After Taxes-(78.85M)(76.89M)(37.60M)(37.29M)[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-7884800000,"profit":false},{"date":"2021-12-31","value":-7689400000,"profit":false},{"date":"2022-12-31","value":-3759700000,"profit":false},{"date":"2023-12-31","value":-3728710500,"profit":false}]
Income From Continuous Operations(117.80M)(79.98M)(78.75M)(37.73M)(36.46M)[{"date":"2019-12-31","value":-11779600000,"profit":false},{"date":"2020-12-31","value":-7997600000,"profit":false},{"date":"2021-12-31","value":-7875100000,"profit":false},{"date":"2022-12-31","value":-3773000000,"profit":false},{"date":"2023-12-31","value":-3645600000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(177.92M)(78.85M)(76.89M)(37.60M)(35.14M)[{"date":"2019-12-31","value":-17791800000,"profit":false},{"date":"2020-12-31","value":-7884800000,"profit":false},{"date":"2021-12-31","value":-7689400000,"profit":false},{"date":"2022-12-31","value":-3759700000,"profit":false},{"date":"2023-12-31","value":-3514000000,"profit":false}]
EPS (Diluted)(0.69)(0.39)(0.37)(0.18)(0.61)[{"date":"2019-12-31","value":-69,"profit":false},{"date":"2020-12-31","value":-39,"profit":false},{"date":"2021-12-31","value":-37,"profit":false},{"date":"2022-12-31","value":-18,"profit":false},{"date":"2023-12-31","value":-61,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

TCRT
Cash Ratio 2.04
Current Ratio 4.30

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

TCRT
ROA (LTM) -40.33%
ROE (LTM) -141.72%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

TCRT
Debt Ratio Lower is generally better. Negative is bad. 0.23
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.77

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

TCRT
Trailing PE NM
Forward PE NM
P/S (TTM) 370.57
P/B 0.95
Price/FCF 0
EV/R 724.36
EV/Ebitda NM

FAQs

What is Alaunos Therapeutics Inc share price today?

Alaunos Therapeutics Inc (TCRT) share price today is $1.62

Can Indians buy Alaunos Therapeutics Inc shares?

Yes, Indians can buy shares of Alaunos Therapeutics Inc (TCRT) on Vested. To buy Alaunos Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in TCRT stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Alaunos Therapeutics Inc be purchased?

Yes, you can purchase fractional shares of Alaunos Therapeutics Inc (TCRT) via the Vested app. You can start investing in Alaunos Therapeutics Inc (TCRT) with a minimum investment of $1.

How to invest in Alaunos Therapeutics Inc shares from India?

You can invest in shares of Alaunos Therapeutics Inc (TCRT) via Vested in three simple steps:

  • Click on Sign Up or Invest in TCRT stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Alaunos Therapeutics Inc shares
What is Alaunos Therapeutics Inc 52-week high and low stock price?

The 52-week high price of Alaunos Therapeutics Inc (TCRT) is $26. The 52-week low price of Alaunos Therapeutics Inc (TCRT) is $1.5.

What is Alaunos Therapeutics Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Alaunos Therapeutics Inc (TCRT) is 0.95

What is the Market Cap of Alaunos Therapeutics Inc?

The market capitalization of Alaunos Therapeutics Inc (TCRT) is $2.59M

What is Alaunos Therapeutics Inc’s stock symbol?

The stock symbol (or ticker) of Alaunos Therapeutics Inc is TCRT

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top